Target Name: IL20RB
NCBI ID: G53833
Review Report on IL20RB Target / Biomarker Content of Review Report on IL20RB Target / Biomarker
IL20RB
Other Name(s): Fibronectin type III domain containing 6 | IL-20RB | DIRS1 | IL-20 receptor subunit beta | I20RB_HUMAN | interleukin 20 receptor beta subunit | IL-20R-beta | IL-20R2 | FNDC6 | interleukin 20 receptor subunit beta | Interleukin 20 receptor subunit beta | interleukin-20 receptor II | Interleukin-20 receptor subunit beta | fibronectin type III domain containing 6

IL20RB: A Potential Drug Target and Biomarker for Inflammatory Lung Disease

Inflammatory lung disease is a serious and progressive condition that can lead to chronic inflammation, lung fibrosis, and even death. IL20RB, a protein produced by immune cells in response to bacterial and viral infections, has been identified as a potential drug target and biomarker for this disease. In this article, we will discuss the research on IL20RB and its potential as a drug target and biomarker for inflammatory lung disease.

The Role of IL20RB in Inflammatory Lung Disease

IL20RB is a cytoplasmic protein that is expressed in a variety of tissues, including the lungs, spleen, and lymph nodes. It is a member of the IL20 family of cytokines, which are a group of pro-inflammatory cytokines that play a crucial role in the immune response. IL20RB is involved in the regulation of inflammation and immune cell function.

Studies have shown that IL20RB is involved in the pathogenesis of a variety of inflammatory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and chronic lung disease. In these diseases, IL20RB is expressed in the immune cells and is involved in the regulation of their functions, such as T cell activation, inflammation, and fibrosis.

IL20RB as a Drug Target

IL20RB has been identified as a potential drug target for inflammatory lung disease due to its involvement in the regulation of immune cell functions and its role in the pathogenesis of these diseases. Several studies have shown that inhibiting IL20RB activity can suppress the production of pro-inflammatory cytokines and improve the symptoms of these diseases.

One of the potential strategies for targeting IL20RB is the use of small molecules, such as those that can inhibit the activity of IL20RB. Several studies have shown that these molecules have the potential to treat inflammatory lung disease by suppressing the production of pro-inflammatory cytokines and improving the function of immune cells.

IL20RB as a Biomarker

IL20RB has also been identified as a potential biomarker for inflammatory lung disease. The levels of IL20RB have been shown to be elevated in the lungs of individuals with respiratory infections, including pneumonia and asthma. This suggests that IL20RB may be a useful biomarker for these diseases.

In addition to its potential as a drug target, IL20RB has also been shown to be a potential biomarker for inflammatory lung disease. The levels of IL20RB have been shown to be elevated in the lungs of individuals with respiratory infections, including pneumonia and asthma. This suggests that IL20RB may be a useful biomarker for these diseases.

Conclusion

IL20RB is a protein produced by immune cells in response to bacterial and viral infections that has been identified as a potential drug target and biomarker for inflammatory lung disease. The regulation of IL20RB activity is involved in the pathogenesis of a variety of inflammatory diseases, including asthma, COPD, and chronic lung disease.

In conclusion, the potential of IL20RB as a drug target and biomarker for inflammatory lung disease makes it an attractive target for future research. Further studies are needed to fully understand the role of IL20RB in the pathogenesis of these diseases and to develop effective treatments.

Protein Name: Interleukin 20 Receptor Subunit Beta

Functions: The IL20RA/IL20RB dimer is a receptor for IL19, IL20 and IL24. The IL22RA1/IL20RB dimer is a receptor for IL20 and IL24

The "IL20RB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IL20RB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

IL21 | IL21-AS1 | IL21R | IL21R-AS1 | IL22 | IL22RA1 | IL22RA2 | IL23A | IL23R | IL24 | IL25 | IL26 | IL27 | IL27RA | IL2RA | IL2RB | IL2RG | IL3 | IL31 | IL31RA | IL32 | IL33 | IL34 | IL36A | IL36B | IL36G | IL36RN | IL37 | IL3RA | IL4 | IL4I1 | IL4R | IL5 | IL5RA | IL6 | IL6-AS1 | IL6R | IL6R-AS1 | IL6ST | IL6ST-DT | IL6STP1 | IL7 | IL7R | IL9 | IL9R | IL9RP3 | IL9RP4 | ILDR1 | ILDR2 | ILF2 | ILF3 | ILF3-DT | ILK | ILKAP | ILRUN | ILVBL | Imidazoline I2 receptor (I2) | Imidazoline I3 receptor (I3) | Imidazoline receptor | IMMP1L | IMMP2L | IMMT | IMMTP1 | Immunoglobulin A | Immunoglobulin E (IgE) | Immunoglobulin G | Immunoglobulin M | Immunoglobulin-Like Domain Containing Receptor | Immunoproteasome | IMP3 | IMP4 | IMPA1 | IMPA1P1 | IMPA2 | IMPACT | IMPDH1 | IMPDH1P10 | IMPDH1P6 | IMPDH2 | IMPG1 | IMPG2 | INA | INAFM1 | INAFM2 | INAVA | INCA1 | INCENP | INE1 | INE2 | INF2 | ING1 | ING2 | ING2-DT | ING3 | ING4 | ING5 | INGX | INHA | INHBA | INHBA-AS1